Following systemic therapy in metastatic colorectal cancer(mCRC),RAS (including KRAS, NRAS and HRAS gene) status may change from a mutant(MT) to a wild-type(WT),a phenomenon known as "NeoRAS WT"mCRC.NeoRAS WT can be detected by longitudinal circulating tumor DNA(ctDNA) analysis.Therefore, this prospective phase II Study was design to explore the detection rate of peripheral blood ctDNA testing for NeoRAS WT and its guiding value for subsequent treatment for mCRC.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
1,100
Cetuximab is given In patients with NeoRAS WT
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
RECRUITINGDetection rate of NeoRAS WT
Proportion of occurrence of neoRAS WT
Time frame: up to 60 months
Objective response rate(ORR) of NeoRAS wild-type patients receiving anti-EGFR therapy
Objective response rate of NeoRAS wild-type patients receiving anti-EGFR (epidermal growth factor receptor) therapy
Time frame: Follow-up was conducted for 2 years after enrollment
Progression-free survival (PFS) in NeoRAS WT patients
Progression-free survival (PFS) : time from enrollment to disease progression from any cause
Time frame: Follow-up was conducted for 2 years after enrollment
Overall survival (OS) in NeoRAS WT patients
Overall survival (OS) : time from enrollment to death from any cause, loss of participants, and time of last follow-up
Time frame: Follow-up was conducted for 2 years after enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.